HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) All Versions of this Article: 0091270009335766v1 49/7/865    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Google Scholar Articles by Mymin, D. Articles by Friesen, M. H. PubMed PubMed Citation Articles by Mymin, D. Articles by Friesen, M. H. Social Bookmarking                         What's this?

Iatrogenic Severe Depression of High-Density Lipoprotein Cholesterol

From the Section of Cardiology, Department of Internal Medicine (Dr Mymin); Department of Clinical Chemistry, Health Sciences Centre, and Department of Biochemistry and Medical Genetics (Dr Dembinski); and Faculty of Pharmacy and Department of Pharmacy, Health Sciences Centre (Dr Friesen), University of Manitoba, Winnipeg, Canada.

The authors present 5 cases of paradoxical depression of high-density lipoprotein (HDL) cholesterol induced by fibrate drugs. In a 24-month review of all cases seen in one physician's practice at the Winnipeg Health Sciences Centre Lipid Clinic, 492 patients made a total of 1187 visits. Sixty-eight of them were given a fibrate drug (14%). Ten patients had HDL cholesterol levels that were less than 0.5 mmol/L (2%), and of these, 5 cases were due to exposure to fenofibrate (1%). These 5 cases comprised 7.4% of the 68 patients who were given any fibrate drug during that period. Mean levels were as follows: HDL cholesterol on fenofibrate 0.27, off fenofibrate 1.0 mmol/L and apo A1 on fenofibrate 0.41, off fenofibrate 1.17 g/L. A literature review revealed documented cases in 37 patients involving fibrates alone or in combination with other drugs known to cause decreased HDL cholesterol levels. In 13 patients, exposure was to fibrate therapy alone; in those exposed to combinations, the effect was clearly attributable to fibrates in 9; in 14, the nonfibrates (mostly rosiglitazone) were the attributable drugs; and in 1, it was impossible to tell. Thus, fibrate therapy should always be suspected as a cause of profoundly depressed HDL cholesterol.

Key Words: Fibric acid derivatives • HDL • lipid disorders • adverse drug reactions

Address for reprints: David Mymin, MD, Health Sciences Centre, MS755D—820 Sherbrook Street, Winnipeg, MB R3A 1R9, Canada; e-mail: dmymin{at}cc.umanitoba.ca.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?